Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM) is a malignant plasma cell (PC) disorder, characterized by a complex interactive network of tumour cells and the bone marrow (BM) stromal microenvironment, contributing to MM cell survival, proliferation and chemoresistance. Mesenchymal stem cells (MSCs) represent the predominant stem cell population of the bone marrow stroma, capable of differentiating into multiple cell lineages, including fibroblasts, adipocytes, chondrocytes and osteoblasts. MSCs can migrate towards primary tumours and metastatic sites, implying that these cells might modulate tumour growth and metastasis. However, this issue remains controversial and is not well understood. Interestingly, several recent studies have shown functional abnormalities of MM patient-derived MSCs indicating that MSCs are not just by-standers in the BM microenvironment but rather active players in the pathophysiology of this disease. It appears that the complex interaction of MSCs and MM cells is critical for MM development and disease outcome. This review will focus on the current understanding of the biological role of MSCs in MM as well as the potential utility of MSC-based therapies in this malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328 · cited 23×
“[2] have observed a distinctive gene expression profile between MM-MSCs and ND-MSCs, with differential expression of genes coding for growth and angiogenic factors, as well as for factors related to bone differentiation.”
BackgroundInfluentialGiuliani, N., Colla, S., Sala, R., Moroni, M., Lazzaretti, M., La Monica, S., Bonomini, S., Hojden, M., Sammarelli, G., Barillè, S., et al. (2002) · Blood · doi:10.1182/blood-2002-04-1121 · Cited by 270 · cited 3×
“TGF-β TGF-β receptor inhibitor [82] IL7 Anti-IL-7 antibody [70, 81]”
BackgroundRANK ligand and osteoprotegerin in myeloma bone disease.
Sezer, O., Heider, U., Zavrski, I., Kühne, C. A., & Hofbauer, L. C. (2003) · Blood · doi:10.1182/blood-2002-09-2684 · Cited by 258
Arnulf, B., Lecourt, S., Soulier, J., Ternaux, B., Lacassagne, M.-N., Crinquette, A., Dessoly, J., Sciaini, A.-K., Benbunan, M., Chomienne, C., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404466 · Cited by 190
Standal, T., Abildgaard, N., Fagerli, U.-M., Stordal, B., Hjertner, Ø., Borset, M., & Sundan, A. (2007) · Blood · doi:10.1182/blood-2006-07-034884 · Cited by 167
Garayoa, M., Garcia, J. L., Santamaria, C., Garcia-Gomez, A., Blanco, J. F., Pandiella, A., Hernández, J. M., Sanchez-Guijo, F. M., del Cañizo, M.-C., Gutiérrez, N. C., et al. (2009) · Leukemia · doi:10.1038/leu.2009.65 · Cited by 148 · cited 2×
“However, to which extent these molecular aberrations in MM-MSCs may have an impact on their function and, thus, on the progression/relapse of MM disease still remains to be determined [8].”
BackgroundEvidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
André, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., & Lagneaux, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059756 · Cited by 107 · cited 2×
“[7] demonstrated that MM BM-derived MSCs exhibited an increased expression of senescence-associated β-galactosidase, increased cell size, reduced proliferative capacity and characteristic expression of senescence-”
BackgroundXu, S., Menu, E., Becker, A. D., Van Camp, B., Vanderkerken, K., & Van Riet, I. (2012) · Stem Cells · doi:10.1002/stem.787 · Cited by 103
Self-citationXu, S., De Veirman, K., Evans, H., Santini, G. C., Vande Broek, I., Leleu, X., De Becker, A., Van Camp, B., Croucher, P., Vanderkerken, K., et al. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.182 · Cited by 64 · cited 8×
“Vorinostat (SAHA or ZolinzaTM) is a pan-inhibitor of class I and II HDAC proteins.”
BackgroundResultInfluentialSelf-citationMesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway
Atsuta, I., Liu, S., Miura, Y., Akiyama, K., Chen, C., An, Y., Shi, S., & Chen, F.-M. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt322 · Cited by 57 · cited 1×
“[44] demonstrated that Fas/FasL-induced MM apoptosis played a crucial role in the MSCbased inhibition of MM growth [44].”
BackgroundBerenstein, R., Blau, O., Nogai, A., Waechter, M., Slonova, E., Schmidt-Hieber, M., Kunitz, A., Pezzutto, A., Doerken, B., & Blau, I. W. (2015) · BMC Cancer · doi:10.1186/s12885-015-1078-3 · Cited by 44 · cited 1×
“MM cells could reduce the expression of miR223 and miR-485-5p in vitro, which altered the senescence phenotype of MM-MSCs with participation of the delta-like homologue 1- iodothyronine deiodinase 3 (DLK1-DIO3) genomic region [11].”
BackgroundKanehira, M., Fujiwara, T., Nakajima, S., Okitsu, Y., Onishi, Y., Fukuhara, N., Ichinohasama, R., Okada, Y., & Harigae, H. (2017) · Stem Cells · doi:10.1002/stem.2499 · Cited by 42 · cited 2×
“Therefore, during the different stages and conditions, MSCs might exhibit different effects on MM growth [48].”
BackgroundAngiogenic activity of mesenchymal stem cells in multiple myeloma
Wang, X., Zhang, Z., & Yao, C. (2011) · Cancer Investigation · doi:10.3109/07357907.2010.496758 · Cited by 32
Cited by
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
García-Ortiz, A., Rodríguez-García, Y., Encinas, J., Maroto-Martín, E., Castellano, E., Teixidó, J., & Martínez-López, J. (2021) · Cancers · doi:10.3390/cancers13020217 · Cited by 238
Garcia-Gomez, A., Li, T., de la Calle-Fabregat, C., Rodríguez-Ubreva, J., Ciudad, L., Català-Moll, F., Godoy-Tena, G., Martín-Sánchez, M., San-Segundo, L., Muntión, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20715-x · Cited by 57
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
Liu, Z., Mi, F., Han, M., Tian, M., Deng, L., Meng, N., Luo, J., & Fu, R. (2021) · Clinical and Experimental Immunology · doi:10.1111/cei.13594 · Cited by 29
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27
Metadata
- Authors
- Xu, S., De Veirman, K., De Becker, A., Vanderkerken, K., & Van Riet, I.
- Venue
- Leukemia
- Published
- 2018-02-22
- Volume
- 32
- Issue
- 7
- Pages
- 1500-1514
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2790634003
- Cited by
- 111
- References
- 13
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.